Skip to main content

Table 2 Biologics combined 3-, 6-, and 12-month outcome data (ACR20/ACR50/ACR70), adjusted for control event rate

From: Applying science in practice: the optimization of biological therapy in rheumatoid arthritis

  Combined 3-, 6-, and 12-month outcome data: relative risk (95% confidence interval) versus placebo
ACR20  
   Abatacept 1.72 (1.38 to 2.15)
   Adalimumab 2.08 (1.71 to 2.52)
   Etanercept 2.09 (1.58 to 2.77)
   Infliximab 1.71 (1.23 to 2.38)
   Rituximab 1.93 (1.40 to 2.56)
ACR50  
   Abatacept 2.29 (1.62 to 3.24)
   Adalimumab 3.05 (2.29 to 4.07)
   Etanercept 2.93 (1.94 to 4.44)
   Infliximab 2.16 (1.36 to 3.41)
   Rituximab 2.92 (1.76 to 4.83)
ACR70  
   Abatacept 3.40 (2.10 to 4.94)
   Adalimumab 4.01 (2.71 to 5.92)
   Etanercept 3.02 (1.94 to 4.70)
   Infliximab 2.49 (1.47 to 4.24)
   Rituximab 4.48 (2.12 to 9.45)
  1. Data extracted from Singh and colleagues [36]. ACR20, American College of Rheumatology 20% improvement criteria; ACR50, American College of Rheumatology 50% improvement criteria; ACR70, American College of Rheumatology 70% improvement criteria.